WuXi Biologics Again Passed GMP Inspection by Japan PMDA

Core Insights - WuXi Biologics has successfully passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities, MFG2 and MFG5, in Wuxi city, indicating strong compliance with global regulatory standards [1][2] - The company has a proven track record, having passed 42 regulatory inspections and received 97 license approvals from various drug administration agencies across multiple regions, including the U.S., Europe, China, Singapore, Japan, and Canada [3] - WuXi Biologics employs over 12,000 skilled employees globally and is currently supporting 817 integrated client projects, with 21 in commercial manufacturing, excluding COVID-related projects [5] Company Overview - WuXi Biologics is a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) that provides end-to-end solutions for the discovery, development, and manufacturing of biologics [4] - The company emphasizes Environmental, Social, and Governance (ESG) responsibilities as a core part of its business strategy, aiming to become a leader in ESG within the biologics CRDMO sector [6]